Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Medical Center Groningen
With
Dutch Cancer Society
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
1. Histologically proven initial diagnosis of adenocarcinoma of the Prostate.
2. Biochemical recurrence of prostate cancer following primary local prostate treatment (radical prostatectomy, primary radiotherapy or radical prostatectomy +/- prostate bed adjuvant salvage radiotherapy) according to the EAU guidelines 2018. BCR after surgery: PSA \> 0.1ng/ml. BCR after radiotherapy: PSA nadir +2 ng/ml or 3 consequent rises in PSA level (after exclusion of possible bounce effect).
3. Minimal 1 lesion and maximum 4 lesions (bone + lymph nodes) in total, without evidence of visceral metastases.
1. Nodal relapse (N1) in the pelvis on PSMA-PET/CT with a maximum of 4 positive lymph nodes. The upper limit of the pelvis is defined as the aortic bifurcation.
2. Nodal relapse (M1a) on PSMA-PET/CT above the aortic bifurcation with a maximum of 3 positive lymph nodes.
3. Bone relapse on PSMA-PET/CT with a maximum of 3 lesions.
4. Combination of a, b, c with a maximum of 4 metastases.
4. Age \> 18 years.
5. Recent PSMA-PET/CT scan within 60 days prior to randomization.
6. PSA \< 10 ng/ml.
7. In case of chronic use of finasteride the PSA value should be \< 5 ng/ml.
8. WHO performance state 0-2.
9. Signed informed consent prior to registration/randomization.
